.png){kind=icon}
.png){kind=icon}
Return
Mutation-centric kinase drug repurposing for rare cancers
.png){kind=icon}
PRE
AI
M
H
V
T
DOI：10.1038/s41568-026-00944-w.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Rare cancers remain underserved by precision oncology, in part because many oncogenic variants lack matched therapies despite a growing arsenal of targeted drugs. We propose that systematic, variant-level pharmacological mapping of approved kinase inhibitors can transform this gap into an opportunity for scalable drug repurposing. Rare cancers remain underserved by precision oncology, in part because many oncogenic variants lack matched therapies despite a growing arsenal of targeted drugs. In this Comment, the authors propose that systematic, variant-level pharmacological mapping of approved kinase inhibitors can transform this gap into an opportunity for scalable drug repurposing.
Journal
IF:
66.8
Papers:
3.8K
Citations:
6.0W
Organization
Cited Papers